Canada markets closed

Revive Therapeutics Ltd. (RVVTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3280-0.0163 (-4.73%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3443
Open0.3690
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3236 - 0.3690
52 Week Range0.1200 - 0.5100
Volume471,036
Avg. Volume611,761
Market Cap104.832M
Beta (5Y Monthly)-0.39
PE Ratio (TTM)N/A
EPS (TTM)-0.0560
Earnings DateMay 30, 2022 - Jun 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Baystreet

    Stocks in play: Revive Therapeutics Ltd

    Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...

  • GlobeNewswire

    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

    The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3

  • GlobeNewswire

    PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

    Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM)